Sulfonylurea adherence and glycemic control in native Americans with type 2 diabetes mellitus

Michael W. Kruse; Michael S. Monaghan; Thomas J. Troshynski

doi:10.1300/J055v08n01_03

Sulfonylurea adherence and glycemic control in native Americans with type 2 diabetes mellitus

Michael W. Kruse, Michael S. Monaghan, Thomas J. Troshynski

Department of Pharmacy Practice

Research output: Contribution to journal › Article › peer-review

Abstract

The purpose of this study was to assess adherence to sulfonylurea monotherapy within a Native American population with type 2 diabetes mellitus. Patient medication adherence was evaluated using medical records to perform a 12-month, cross-sectional evaluation of medication refills. Adherence was defined using a continuous, multiple-interval measure of medication availability (CMA). Patients had an average of 80.5 ± 25.4 days of medication during 100 days of treatment, equivalent to a defined adherence scale of fair to poor in 58%. Because CMA may be less expensive and time- consuming than other measures of medication adherence, CMA can be used to assess medication adherence in patients at risk for developing diabetes complications, such as Native Americans.

Original language	English (US)
Pages (from-to)	41-49
Number of pages	9
Journal	Journal of Pharmacoepidemiology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1300/J055v08n01_03
State	Published - Jan 1 2000

All Science Journal Classification (ASJC) codes

Pharmacology, Toxicology and Pharmaceutics(all)
Pharmacology (medical)

Access to Document

10.1300/J055v08n01_03

Cite this

@article{4a6cc7d42e88479dbe0d183e1add70f9,

title = "Sulfonylurea adherence and glycemic control in native Americans with type 2 diabetes mellitus",

abstract = "The purpose of this study was to assess adherence to sulfonylurea monotherapy within a Native American population with type 2 diabetes mellitus. Patient medication adherence was evaluated using medical records to perform a 12-month, cross-sectional evaluation of medication refills. Adherence was defined using a continuous, multiple-interval measure of medication availability (CMA). Patients had an average of 80.5 ± 25.4 days of medication during 100 days of treatment, equivalent to a defined adherence scale of fair to poor in 58%. Because CMA may be less expensive and time- consuming than other measures of medication adherence, CMA can be used to assess medication adherence in patients at risk for developing diabetes complications, such as Native Americans.",

author = "Kruse, {Michael W.} and Monaghan, {Michael S.} and Troshynski, {Thomas J.}",

year = "2000",

month = jan,

day = "1",

doi = "10.1300/J055v08n01_03",

language = "English (US)",

volume = "8",

pages = "41--49",

journal = "Journal of Pharmacoepidemiology",

issn = "0896-6966",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Sulfonylurea adherence and glycemic control in native Americans with type 2 diabetes mellitus

AU - Kruse, Michael W.

AU - Monaghan, Michael S.

AU - Troshynski, Thomas J.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The purpose of this study was to assess adherence to sulfonylurea monotherapy within a Native American population with type 2 diabetes mellitus. Patient medication adherence was evaluated using medical records to perform a 12-month, cross-sectional evaluation of medication refills. Adherence was defined using a continuous, multiple-interval measure of medication availability (CMA). Patients had an average of 80.5 ± 25.4 days of medication during 100 days of treatment, equivalent to a defined adherence scale of fair to poor in 58%. Because CMA may be less expensive and time- consuming than other measures of medication adherence, CMA can be used to assess medication adherence in patients at risk for developing diabetes complications, such as Native Americans.

AB - The purpose of this study was to assess adherence to sulfonylurea monotherapy within a Native American population with type 2 diabetes mellitus. Patient medication adherence was evaluated using medical records to perform a 12-month, cross-sectional evaluation of medication refills. Adherence was defined using a continuous, multiple-interval measure of medication availability (CMA). Patients had an average of 80.5 ± 25.4 days of medication during 100 days of treatment, equivalent to a defined adherence scale of fair to poor in 58%. Because CMA may be less expensive and time- consuming than other measures of medication adherence, CMA can be used to assess medication adherence in patients at risk for developing diabetes complications, such as Native Americans.

UR - http://www.scopus.com/inward/record.url?scp=0033992135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033992135&partnerID=8YFLogxK

U2 - 10.1300/J055v08n01_03

DO - 10.1300/J055v08n01_03

M3 - Article

AN - SCOPUS:0033992135

VL - 8

SP - 41

EP - 49

JO - Journal of Pharmacoepidemiology

JF - Journal of Pharmacoepidemiology

SN - 0896-6966

IS - 1

ER -

Sulfonylurea adherence and glycemic control in native Americans with type 2 diabetes mellitus

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this